Candel Names Mark Sims as CCO, Eyes Q4 2026 BLA for Prostate Cancer Therapy
CADL•Candel Therapeutics appointed oncology veteran Mark Sims as Chief Commercial Officer to lead launch preparations for aglatimagene besadenovec in intermediate- to high-risk localized prostate cancer. The company plans a Biologics License Application submission in Q4 2026 targeting a potential 2027 launch to address 65,000 annual U.S. cases.
1. Appointment Details
Candel Therapeutics appointed Mark Sims as Chief Commercial Officer effective July 6, 2026. He will lead commercial strategy and launch readiness for aglatimagene besadenovec in intermediate- to high-risk localized prostate cancer.
2. BLA Submission and Launch Plans
The company plans to submit a Biologics License Application for aglatimagene besadenovec in Q4 2026. Commercial preparations span market access, medical affairs, manufacturing, physician engagement and launch planning, targeting a potential 2027 U.S. launch.
3. Market Opportunity
Intermediate- to high-risk localized prostate cancer represents approximately 65,000 new U.S. diagnoses annually. Candel estimates this defined patient population is a major market for radiotherapy-based treatment combined with aglatimagene’s novel immuno-oncology mechanism.
4. Leadership Background and Partnerships
Sims brings over 25 years’ oncology commercial experience from AstraZeneca and Novartis, where he led global cancer franchises. Candel has adopted a partnership-driven model with EVERSANA on commercialization and IDEA Pharma for strategic positioning to ensure capital efficiency and access to commercial capabilities.
